undamentalytics Newsletter
Sign in

Edwards Lifesciences cash flow statement

In fiscal 2025, Edwards Lifesciences's operations generated $1.60bn of cash; it spent $260m on capital projects, leaving free cash flow of $1.33bn. It returned $893m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations1652513083624731,0225507041,0019271,1831,0541,7321,2188965421,5951,720
Depreciation and amortisation5957585463696671827789107135140145155157166
Stock-based pay282935424748505762718193109127139162158168
Capital spending64627710910983103176168239254407326245253252260287
Free cash flow1011902322533649394475288336889296471,4069746432901,3351,434
Free cash flow after stock pay731601972113168913974717716178475551,2978475031281,1771,266
Share buybacks962003033444973012806627637962636255131,7278801,1598931,204

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: EW vs STEEW vs RMDBLCO vs EWEW vs ZBH

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Edwards Lifesciences's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Edwards Lifesciences.